Search results - 14 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Patricia CJL; Gomez, Verónica; Lesieur, Zineb; Barbezange, Cyril; van Nedervelde, Els; Borg, Maria-Louise; Castilla, Jesús; Lazar, Mihaela; O’Donnell, Joan; Jonikaite, Indrė; Demlová, Regina; Amerali, ...
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.
https://sciensano.be/en/10.1016/S2666-5247%2823%2900344-0 Version: Published Full text language: English Category: Peer-reviewed scientific articles FOS Classification: 3 MEDICAL AND HEALTH SCIENCES ...
Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022.
Dimitrijevic, Dragana; Druc, Alina; Apostol, Mariana; Kalasnikova, Kate Karolina; Nikisins, Sergejs; Reiche, Janine; Cai, Wei; Meijer, Adam; Teirlinck, Anne; Larrauri, Amparo; Casas, Inmaculada; Enouf, Vincent; ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
Patricia CJL; Gomez, Verónica; Lesieur, Zineb; Barbezange, Cyril; van Nedervelde, Els; Borg, Maria-Louise; Castilla, Jesús; Lazar, Mihaela; O'Donnell, Joan; Jonikaite, Indrė; Demlová, Regina; Amerali, ...
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions
Keše, Darja; Nir-Paz, Ran; Elinav, Hila; Michael-Gayego, Ayelet; Oishi, Tomohiro; Saraya, Takeshi; Kenri, Tsuyoshi; Hsieh, Yu-Chia; Wu, Tsung-Hua; Maiwald, Matthias; Loo, Liat Hui; Sagar, Tanu; Chaudhry, ...
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
(0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)).ConclusionNAI ...
Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00190-2/fullt… File: Version: Published Full text access: Public Access Full text language: English Category: A1 FOS Classification: 3.03 Health sciences ...
Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015-20: a surveillance study.
66; p=0·017), and in teenagers and adults (≥15 years), more complications arose in patients with a single hCoV infection (49 [45·0%] of 109; p=0·0097). In early 2020, the Belgian SARI surveillance ...
Evaluation of the added value of viral genomic information for predicting severity of influenza infection
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06510-z File: Version: Published Full text access: Public Access Full text language: English Category: A1 FOS Classification: 3.03 Health sciences ...